Blood test measures systemic calcification propensity

Cardiovascular disease is a major cause of morbidity and mortality and a challenge for health-care systems worldwide. It is the number one cause of death of chronic kidney disease (CKD) patients.

As its lead product, Calciscon commercializes the only diagnostic test currently available for the measurement of systemic calcification propensity (Calciscon renal). Kidney patients, which represent approximately 4-5% of the population in developed countries, are the first to benefit from Calciscon renal.